Cross-laboratory analytical validation of the cardiac biomarker NT-proANP in rat.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of pharmacological and toxicological methods

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vascn.2015.10.002PMID 26516096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analytic validation and comparison of three commercial immunoassays for measurement of plasma atrial/A-type natriuretic peptide concentration in horses.

  2014cited by this paper
• Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

  2014cited by this paper
• Hirsutanol A, a novel sesquiterpene compound from fungus Chondrostereum sp., induces apoptosis and inhibits tumor growth through mitochondrial-independent ROS production: Hirsutanol A inhibits tumor growth through ROS production

  2013cited by this paper
• Natriuretic Peptides as Biomarkers in Heart Failure

  2013cited by this paper
• A proteomic view of isoproterenol induced cardiac hypertrophy: Prohibitin identified as a potential biomarker in rats

  2013cited by this paper
• Atrial natriuretic peptides in Han Wistar, Sprague–Dawley and spontaneously Hypertensive rats

  2012cited by this paper
• An initial characterization of N-terminal-proatrial natriuretic peptide in serum of Sprague Dawley rats.

  2011cited by this paper
• Detection of left ventricular hypertrophy in rats administered a peroxisome proliferator-activated receptor alpha/gamma dual agonist using natriuretic peptides and imaging.

  2010cited by this paper
• Circulating natriuretic peptides in cats with heart disease.

  2008cited by this paper
• Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure

  2005cited by this paper
• Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients.

  2005cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats.

  2004cited by this paper
• Clinical validation of a proANP 31-67 fragment ELISA in the diagnosis of heart failure in the dog.

  2003cited by this paper
• Relationship between different natriuretic peptides and severity of naturally acquired mitral regurgitation in dogs with chronic myxomatous valve disease.

  2000cited by this paper
• Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective.

  2000cited by this paper
• Comparison of the diagnostic value of cardiac troponin I and T determinations for detecting early myocardial damage and the relationship with histological findings after isoprenaline-induced cardiac injury in rats.

  2000cited by this paper
• Atrial Natriuretic Factor and Brain Natriuretic Peptide Gene Expression in the Spontaneous Hypertensive Rat During Postnatal Development

  1998cited by this paper
• Atrial natriuretic factor and brain natriuretic peptide gene expression in the spontaneous hypertensive rat during postnatal development.

  1998cited by this paper
• Atrial natriuretic peptide: synthesis, release, and metabolism.

  1992cited by this paper
• Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide.

  1991cited by this paper
• Structure of dog and rabbit precursors of atrial natriuretic polypeptides deduced from nucleotide sequence of cloned cDNA.

  1985cited by this paper

• Post-cardiac arrest temporal evolution of left ventricular function in a rat model: speckle-tracking echocardiography and cardiac circulating biomarkers

  2024cites this paper
• Characterization of the Cardiac Structure and Function of Conscious D2.B10-Dmdmdx/J (D2-mdx) mice from 16–17 to 24–25 Weeks of Age

  2023cites this paper
• Protective Effect of Triclosan in Monocrotaline-Induced Pulmonary Arterial Hypertension: FASN Inhibition a Novel Approach

  2022cites this paper
• Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor.

  2019cites this paper
• Primary pulmonary arterial hypertension: Protocol to assess comprehensively in the rat the response to pharmacologic treatments

  2019cites this paper
• Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac hypertrophy in cell models

  2018cites this paper
• Discover Toxicology: An Early Safety Assessment Approach

  2017cites this paper
• Qualification of safety biomarkers for use in drug development: What has been achieved and what is the path forward?

  2017cites this paper
• Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories

  2016cites this paper
• Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac hypertrophy in cell

  year unknowncites this paper